Key result
Elevated plasma alanine, asparagine, leucine, and valine were associated with increased residual hypertriglyceridemia risk in diabetic patients on statins.
Why the study?
The relationship between amino acid metabolism and hypertriglyceridemia in diabetic patients on statins without prior cardiovascular diseases was unknown.
Are plasma amino acid levels associated with residual hypertriglyceridemia in diabetic patients on statin therapy?
Cross-Sectional (n=440)
Yes
Are plasma amino acid levels associated with residual hypertriglyceridemia in diabetic patients on statin therapy?
Elevated levels of alanine, asparagine, leucine, and valine are associated with an increased residual risk of hypertriglyceridemia in diabetic patients on statin therapy, independent of LDL-C levels.
Answers are grounded in this paper and cite their sources.
May identify amino acid biomarkers for residual hypertriglyceridemia risk in statin-treated diabetes; leaves open causal roles and interventions.
Objective: The objective of the study was to investigate the relationship of amino acid metabolism with hypertriglyceridemia in diabetic patients under statins free of prior cardiovascular diseases. Methods: Two independent cross-sectional hospital based cohorts, i.e., Liaoning Medical University First Affiliated Hospital (LMUFAH, n = 146) and the Second Affiliated Hospital of Dalian Medical University (SAHDMU, n = 294) were included in the current analysis. Hypertriglyceridemia was defined as triglyceride ≥1.7 mmol/L, and well-controlled LDL-C was defined as <2.6 mmol/L. The adjusted ORs (95% CI) of circulating metabolic measures for hypertriglyceridemia were assessed using logistic regression. Pooled results of metabolites with the same direction of association in both cohorts were combined using inverse variance-weighted fixed-effect meta-analysis. Difference of identified metabolites in patients with and without hypertriglyceridemia were also obtained in the context of LDL-C. Results: Patients, 86 and 106, were with hypertriglyceridemia in LMUFAH and SAHDMU, respectively. We observed that elevated alanine, asparagine, leucine, and valine were consistently associated with increased hypertriglyceridemia in both cohorts. In fixed-effect pooled analysis, the OR (95% CI) per SD increase was 1.71 (1.32–2.20) for alanine, 1.62 (1.20–2.19) for asparagine, 1.64 (1.22–2.20) for leucine, and 1.62 (1.22–2.13) for valine (all P values ranged from 0.0018 to <0.0001); adjusting for C-peptide attenuated effect sizes of Ala, Leu, and Val for hypertriglyceridemia. The difference were robust in groups with well- or bad-controlled LDL-C. Conclusion: Among 23 amino acids, alanine, asparagine, leucine, and valine were positively associated with increased residual risk of hypertriglyceridemia in diabetic patients with statin treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a cross-sectional in Type 2 diabetes with residual hypertriglyceridemia (n=440). Elevated plasma amino acids (alanine, asparagine, leucine, valine) vs. Lower plasma amino acid levels was evaluated on Hypertriglyceridemia (TG ≥1.7 mmol/L) per SD increase in alanine (OR 1.71, 95% CI 1.32-2.20, p=<0.0001). Elevated plasma alanine, asparagine, leucine, and valine were associated with increased residual hypertriglyceridemia risk in diabetic patients on statins.
Synapse has enriched 10 related papers. Consider them for comparative context: